Article

New Biosimilar Under Review in Top Specialty Pharmacy News

Author(s):

Davy James, Managing Editor

Catch up with any news you missed this week on Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/new-biosimilar-under-review-in-top-specialty-pharm" target="_blank">View the story "New Biosimilar Under Review in Top Specialty Pharmacy News" on Storify</a>]

Related Videos
Abstract DNA molecule helix inside red blood drop
Woman experiencing pain related to recurrent pericarditis -- Image credit: Art_Photo | stock.adobe.com
Related Content
Exploring the Tumor Microenvironment Interactions Between Cancer Cells, TCells, and Nanoparticles in Cancer Therapy and Immunology
March 31st 2025

NCCN 2025: Managing Immune Checkpoint Inhibitor-Related Toxicities in Cancer Care

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
X-ray image of liver -- Image credit: Sebastian Kaulitzki | stock.adobe.com
March 31st 2025

BEAM-302 Receives FDA IND Clearance for AATD, a Genetic Disorder Affecting the Liver and Lungs

Gillian McGovern, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Kidney dialysis displayed on tablet -- Image credit: frank | stock.adobe.com
March 28th 2025

Peritoneal Dialysis May Be Feasible, Safe Long-Term Treatment for Patients With CKD

Gillian McGovern, Associate Editor
Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services.
March 27th 2025

FDA Approves Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome

Luke Halpern, Assistant Editor